FDA Approves Gattex® (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome

    FDA Approves Gattex® (teduglutide [rDNA Origin]) for Injection for the
                   Treatment of Adult Short Bowel Syndrome

-- First major long-term treatment advance for adult SBS in nearly 40 years --

-- U.S. launch in first quarter of 2013 --

-- NPS Pharmaceuticals to host conference call on January 2, 2013 at 5:00 PM
ET --

PR Newswire

BEDMINSTER, N.J., Dec. 21, 2012

BEDMINSTER, N.J., Dec. 21, 2012 /PRNewswire/ --NPS Pharmaceuticals, Inc.
(NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering
therapies that transform the lives of patients with rare diseases worldwide,
today announced that the U.S. Food and Drug Administration (FDA) has approved
Gattex^® (Teduglutide [rDNA origin]) for Injection, for subcutaneous use for
the treatment of adult patients with short bowel syndrome (SBS) who are
dependent on parenteral support. Gattex will be available in the first quarter
of 2013. For full prescribing information, please visit www.Gattex.com.

To view the multimedia assets associated with this release, please click:
http://www.multivu.com/mnr/59518-nps-pharmaceuticals-fda-approval-gattex-adult-short-bowel-syndrome-sbs

"Gattex is a ground-breaking therapy that has been evaluated in the largest
clinical program to date in short bowel syndrome," said Francois Nader, MD,
president and chief executive officer of NPS Pharmaceuticals. "We are very
excited about the opportunity to help SBS patients by offering this
first-in-class therapy. The approval of Gattex is a crowning achievement for
our company and the catalyst for our transformation into a premier orphan drug
business. We are prepared for a successful launch based on productive
interactions with payers, methodical patient identification, and the strategic
development of our field-based commercial infrastructure. We have also
launched NPS Advantage, our free support program that includes, care
coordinators who will work closely with patients to help them understand the
clinical characteristics of Gattex and navigate the reimbursement landscape."

SBS is a serious, complex disorder in which the body is unable to absorb
enough nutrients and fluids through the gastrointestinal tract to sustain
life. SBS patients are commonly infused with PN/IV five to seven nights per
week for up to 10 to 12 hours at a time, and in extreme cases, some patients
could receive PN/IV for 24 hours a day. Long-term use of PN/ IV fluids can be
associated with life-threatening complications such as liver damage, serious
bloodstream infections, and blood clots.

Gattex is the first major long-term treatment advance for SBS in nearly 40
years. The unique mechanism of action of Gattex enhances gastrointestinal
absorption. In Phase 3 studies, significant reductions in PN/IV volume and
infusion days per week were achieved from pre-treatment baseline. In addition,
some patients achieved independence from PN/IV support.

"In addition to serious medical complications, patients with short bowel
syndrome can have socially-restricted lives. Long infusion periods often
disrupt sleep for patients. This is coupled with constant concern about using
restrooms as many patients will need to use the bathroom up to 25 times a day
or having an accident with unpredictable diarrhea. Other patients that have an
ostomy bag have a fear of an ostomy bag leakage. These factors leave many
patients unable to socialize or work," said Ken Fujioka, MD, Nutrition and
Metabolic Research Center, Scripps Clinic, Del Mar. "Considering Gattex has
been shown to significantly reduce or in some cases even eliminate the
requirement for parenteral support, it may become a cornerstone therapy in the
management of short bowel syndrome."

SBS typically occurs when a large portion of the intestine has been removed by
surgery caused by disease or injury. In rare cases, it is congenital. Common
symptoms of SBS can include diarrhea, dehydration, malnutrition, and weight
loss, which are closely related to the functional issues of the bowel. During
a typical day, SBS patients will move their bowels up to 10 times, or change
their ostomy bag, which collects their urine output, three to four times. In
extreme cases, patients may move their bowels as many as 25 times each day.

"Patients with short bowel syndrome/intestinal failure need a comprehensive
program to receive optimal care so that their quality of life is maintained to
its fullest extent. The Oley Foundation encourages research and new
development of drugs, products and services that improve health and
well-being," said Joan Bishop, executive director, The Oley Foundation. "We
are pleased that NPS Pharmaceuticals has engaged in this research and has set
upon a path that serves to bring hope that it will reduce the challenges of
short bowel syndrome/intestinal failure and improve the quality of life of
many of our members and their families."

NPS Advantage™

To assist patients and healthcare professionals in facilitating care with
Gattex, NPS has launched a free support program called NPS Advantage™. This
program is designed to help navigate all aspects of care, help with insurance
authorizations and appeals, answer questions about Gattex and its use, and
locate resources for patients that connect them to care.

A key feature of NPS Advantage is the involvement of experienced care
coordinators, who provide comprehensive support with a single point of
contact. These NPS professionals will work with Gattex patients to confirm
authorizations and benefit approvals for Gattex and help resolve health
insurance issues. They will also support healthcare professionals to
streamline the reimbursement process for Gattex and help their patients obtain
appropriate medical care. For more information, please visit
http://www.npsadvantage.com.

Conference Call Information

NPS will host a conference call to discuss its commercialization plan for
Gattex, including the cost of therapy, on Wednesday, January 2, 2013 at 5:00
p.m. Eastern Time. To participate in the conference call, dial (800) 706-7748
and use pass code 18085144. International callers may dial (617) 614-3473,
using the same pass code. In addition, a live audio of the conference call
will be available over the Internet. Interested parties can access the event
through the NPS website, http://www.npsp.com.

For those unable to participate in the live call, a replay will be available
at (888) 286-8010, with pass code 79197503, until midnight Eastern Time,
January 16, 2013. International callers may access the replay by dialing
(617) 801-6888, using the same pass code. The webcast will also be available
through the NPS website for the same period.

About Short Bowel Syndrome

Short bowel syndrome (SBS) is a highly disabling condition that can impair a
patient's quality of life and lead to serious life-threatening complications.
SBS typically arises after extensive resection of the bowel due to Crohn's
disease, ischemia or other conditions. SBS patients often suffer from
malnutrition, severe diarrhea, dehydration, fatigue, osteopenia, and weight
loss due to the reduced intestinal capacity to absorb nutrients, water and
electrolytes. The usual treatment for SBS is nutritional support, including
parenteral nutrition (PN) and/or intravenous (IV) fluids to supplement and
stabilize nutritional needs.

Although PN can provide nutritional support for SBS patients, it does not
improve the body's own ability to absorb nutrients. PN is associated with
serious complications, such as infections, blood clots or liver damage, and
the risks increase the longer patients are on PN. Patients on PN often
experience poor quality of life with difficulty sleeping, and frequent
urination, and patients receiving chronic PN often experience a loss of
independence.

Gattex Clinical Trials

NPS' clinical development program for Gattex is the largest and most
comprehensive conducted in SBS patients to date, consisting of 15 clinical
studies. Across all clinical studies, 566 subjects were exposed to at least
one dose of Gattex, of whom 134 had SBS and were treated with 0.05 mg/kg/day
Gattex. The FDA's approval of Gattex was based on an international, 24-week,
double-blind, placebo-controlled, pivotal Phase 3 trial, known as STEPS. The
primary endpoint of STEPS was defined as a 20 percent or greater PN/IV volume
reduction demonstrated at week 20 and sustained at week 24. The study's
secondary endpoints included reductions in PN/IV volume and additional days
off therapy. Key findings from the STEPS trial include:

  oIn an intent-to-treat analysis at weeks 20 and 24, 63 percent of patients
    treated with Gattex achieved at least a 20 percent reduction in weekly
    PN/IV volume when compared to baseline, versus 30 percent for placebo
    (p=0.002).
  oAfter 24 weeks of treatment, PN volume declined by 32 percent (4.4 L/wk)
    in Gattex-treated patients, versus 21 percent (2.3 L/wk) in the placebo
    group (p<0.001).
  oAfter 24 weeks of treatment, 54 percent of Gattex-treated patients were
    able to reduce the number of infusion days per week by one or more days,
    compared to 23 percent of those treated with placebo (p=0.005).

The most common adverse reactions (≥10 percent) across all studies with Gattex
are abdominal pain, injection site reactions, nausea, headaches, abdominal
distension, upper respiratory tract infection. In addition, vomiting and fluid
overload were reported in the Phase 3 SBS studies at rates ≥ 10 percent.

For full prescribing information, please visit www.Gattex.com.

About Gattex^® (teduglutide [rDNA origin]) for Injection

Gattex^® (teduglutide [rDNA origin]) for Injection, for subcutaneous use is a
novel, recombinant analog of human glucagon-like peptide 2, a protein involved
in the rehabilitation of the intestinal lining. Gattex^® 0.05 mg/kg/d
(teduglutide [rDNA origin] for Injection) is indicated for the treatment of
adult patients with short bowel syndrome (SBS) who are dependent on parenteral
support. Significant reductions in mean PN/IV infusion volume from baseline to
end of treatment were seen in the Phase 3 studies of Gattex. In addition, some
patients were able to achieve independence from PN/IV support during these
trials. The most common side effects of Gattex include stomach area (abdomen)
pain or swelling, skin reaction where the injection was given, nausea,
headache, cold or flu like symptoms, vomiting, and holding too much fluid in
the body (swelling of face, ankles, hands or feet).

Gattex has received orphan drug designation for the treatment of SBS from the
European Medicines Agency (EMA) and the FDA.

In 2007, NPS granted Takeda GmbH, the rights to develop and commercialize
teduglutide outside the United States, Canada, Mexico and Israel. NPS retains
all rights to teduglutide in North America. The European Commission granted
European market authorization on August 30, 2012 for the medicinal product
teduglutide (trade name in Europe: Revestive®) as a once-daily treatment for
adult patients with short bowel syndrome.

Teduglutide was discovered by Daniel J. Drucker, MD, currently a senior
scientist based in the Samuel Lunenfeld Research Institute at Mt. Sinai
Hospital, University of Toronto, in Toronto, Canada. NPS has an exclusive
license agreement with Dr. Drucker for teduglutide and its therapeutic uses.

Important Safety Information (ISI)

Gattex has been associated with serious risks including:

  oNeoplastic growth. There is a risk for acceleration of neoplastic growth.
    Colonoscopy of the entire colon with removal of polyps must be done before
    initiating treatment with Gattex and is recommended after 1 year.
    Subsequent colonoscopies should be done as needed, but no less frequently
    than every 5 years. In case of intestinal malignancy discontinue Gattex.
    The clinical decision to continue Gattex in patients with active
    non-gastrointestinal malignancy should be made based on risk and benefit
    considerations.
  oIntestinal obstruction. In patients who develop obstruction, Gattex
    should be temporarily discontinued pending further clinical evaluation and
    management.
  oBiliary and pancreatic disease. Patients should undergo laboratory
    assessment (bilirubin, alkaline phosphatase, lipase, amylase) before
    starting Gattex. Subsequent laboratory tests should be done every 6
    months. If clinically meaningful changes are seen, further evaluation is
    recommended including imaging, and continued treatment with Gattex should
    be reassessed.
  oFluid overload. There is a potential for fluid overload while on Gattex.
    If fluid overload occurs, especially in patients with cardiovascular
    disease, parenteral support should be appropriately adjusted, and Gattex
    treatment reassessed.

Prescribers should select the appropriate patients to receive Gattex in
accordance with the approved prescribing information, discuss the benefits and
risks of Gattex with patients, and monitor patients as specified in the
approved prescribing information and report adverse events to NPS' Gattex
information line at 1-855-5GATTEX (1-855-542-8839) or event/product complaint
line at 1-855-215-5550.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan
products to patients with rare disorders and few, if any, therapeutic options.
The company's lead product, Gattex^® 0.05 mg/kg/d (Teduglutide [rDNA origin])
for Injection is FDA-approved for the treatment of adult patients with short
bowel syndrome (SBS) who are dependent on parenteral support. NPS is also
developing Natpara^® (rhPTH[1-84]) for the treatment of adult
hypoparathyroidism and expects to submit its Biologic License Application
(BLA) to the FDA in mid-2013.

NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790 and
NPSP795, with potential application in rare disorders involving increased
calcium receptor activity, such as autosomal dominant hypocalcemia with
hypercalciuria (ADHH). NPS complements its proprietary programs with a
royalty-based portfolio of products and product candidates that includes
agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko
Kirin, and Takeda GmbH.

"NPS," "NPS Pharmaceuticals," "Gattex," and "Natpara" are the company's
trademarks. All other trademarks, trade names or service marks appearing in
this press release are the property of their respective owners.

Statements made in this press release, which are not historical in nature,
constitute forward-looking statements for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995. These statements are
based on the company's current expectations and beliefs and are subject to a
number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. Forward
looking statements include, but are not limited to, statements concerning our
future commercial performance. Risks associated to the company's business
include, but are not limited to, the risks associated with any failure by the
company to successfully commercialize Gattex, including the risk that
physicians and patients may not see the advantages of Gattex and may therefore
be reluctant to utilize the product, the risk that private and public payers
may be reluctant to cover or provide reimbursement for Gattex, as well as
other risk factors described in the company's periodic filings with the U.S.
Securities and Exchange Commission, including its Annual Report on Form 10-K
and Form 10-Qs. All information in this press release is as of the date of
this release and NPS undertakes no duty to update this information, whether as
a result of new information, future events or otherwise.

SOURCE NPS Pharmaceuticals

Website: http://www.Gattex.com
Website: http://www.npsp.com
Contact: Susan M. Mesco, NPS Pharmaceuticals, Inc., +1-908-450-5516,
smesco@npsp.com, www.npsp.com